Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcus pneumoniae, also known as pneumococcus, is a Gram-positive bacterium responsible for diseases such as pneumonia, meningitis, otitis media, and sepsis. Key features include its thick peptidoglycan cell wall, polysaccharide capsule (with over 98 serotypes), and various surface proteins involved in adhesion and immune evasion. Virulence factors like pneumolysin and the capsule contribute to its pathogenicity. Its high genetic diversity and phase variation impact vaccine effectiveness and antibiotic resistance. As a whole cell target it includes all structural features: thick cell wall with unique modifications/residues important for survival/virulence; diverse capsular types critical for vaccine design/effectiveness; multiple surface-exposed proteins mediating adhesion/immune modulation.
Antibiotics target various bacterial processes (e.g., cell wall synthesis, protein synthesis, DNA replication). Vaccines induce antibody production against capsular polysaccharides or surface proteins.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae (whole cell) (S. pneumoniae).